文献速递乳腺癌放疗放疗物理与技术

剂量去强化三日光子、质子或近距离放疗:一项非随机对照部分乳腺照射试验

Dose Deintensified 3-Day Photon, Proton, or Brachytherapy: A Nonrandomized Controlled Partial Breast Irradiation Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2024-09-17

这项多中心非随机对照试验评估了光子、质子或近距离放疗三日去强化部分乳腺照射方案,主要终点为3年不良美容结局较照射前的变化。161例符合条件的患者接受治疗,3年不良美容结局为2.3%,较基线14.5%下降12.2%(95%CI -100%至-6.4%),达到预设可接受标准。

要点

  • 三日去强化部分乳腺照射方案在光子、质子或近距离放疗中均达到预设可接受标准。
  • 3年不良美容结局为2.3%,较基线14.5%下降12.2%(95%CI -100%至-6.4%)。
  • 中位随访5年,护士评估不良美容结局5.7%,面板评估5.6%,患者自报5.2%。

核心结论

  • 去强化三日部分乳腺照射提供了良好的疾病控制、耐受性和美容结局,达到预设的可接受标准。
  • 作者认为,该方法对于小体积、淋巴结阴性、ER+乳腺癌和DCIS患者是一个有吸引力的选择。

研究设计与样本

  • 多中心非随机对照试验,主要终点为3年不良美容结局与部分乳腺照射前比较。
  • 纳入标准为年龄≥50岁、接受保乳手术的淋巴结阴性ER+浸润性乳腺癌或任何DCIS且病灶≤2.5 cm。
  • 光子与质子部分乳腺照射处方为21.9 Gy(相对生物效应),近距离放疗为21 Gy,均分3次。
  • 放疗技术和辅助内分泌治疗由医生和患者自行选择。
  • 2015年6月17日至2017年7月13日共治疗161例符合条件的患者,其中光子56例、质子49例、近距离放疗56例。

主要发现

  • 患者中位年龄66.8岁;126例(78.3%)为浸润性乳腺癌(均为ER+),35例(21.7%)为DCIS(88.6% ER+)。
  • 54%的浸润性乳腺癌患者和25.8%的ER+ DCIS患者开始并坚持了处方的内分泌治疗。
  • 经培训护士评估的不良美容结局比例在基线为14.5%,3年时为2.3%(差值-12.2%;95%CI -100%至-6.4%)。
  • 中位随访5年时,末次随访不良美容结局:护士评估5.7%,数字照片面板评估5.6%,患者自报5.2%。
  • 5年局部无复发生存率为98.0%,无进展生存率为95.5%;在60例浸润性乳腺癌且Ki67≤13.25%的患者中无局部复发。

关键数值与推荐

  • 光子与质子部分乳腺照射处方剂量为21.9 Gy(相对生物效应),分3次。
  • 近距离放疗处方剂量为21 Gy,分3次。
  • 其他患者报告结局未观察到有临床意义的变化,仅近距离放疗队列发生2例2级或以上不良事件,均为2级。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The optimal approach for partial breast irradiation (PBI) is unknown. We investigated a novel de-intensified 3-fraction PBI regimen for photons, protons, and brachytherapy. METHODS AND MATERIALS: A multicenter nonrandomized controlled trial with the primary outcome of adverse cosmesis at 3 years versus before PBI. Eligibility criteria were age ≥50 years treated with breast-conserving surgery for node-negative estrogen receptor-positive (ER+) invasive breast cancer or any ductal carcinoma in situ (DCIS) measuring ≤2.5 cm. Photon and proton PBI were prescribed 21.9 Gy (relative biological effectiveness) and brachytherapy 21 Gy in 3 fractions. Radiation therapy technique and adjuvant endocrine therapy were selected at physician and patient discretion. RESULTS: Between June 17, 2015, and July 13, 2017, 161 eligible patients were treated with photons (56), protons (49), or brachytherapy (56). Median patient age was 66.8 years. One hundred twenty-six (78.3%) had invasive breast cancer (all ER+) and 35 (21.7%) had DCIS (88.6% ER+). Fifty-four percent of patients with invasive breast cancer and 25.8% of patients with ER+ DCIS initiated and adhered to the prescribed endocrine therapy. The proportion of patients with adverse cosmesis (by trained nurse assessment) was 14.5% at baseline and 2.3% at 3 years (difference, -12.2%; 95% CI, -100% to -6.4%). Adverse cosmesis at the last follow-up, with a median follow-up of 5 years, was 5.7% by nurse assessment, 5.6% by panel assessment of digital photographs, and 5.2% by patient self-report. There were no observed clinically meaningful changes in other patient-reported outcomes, and just 2 grade 2 or higher adverse events, both grade 2, in the brachytherapy cohort. Five-year local recurrence-free survival and progression-free survival were 98.0% and 95.5%, respectively. There were no local recurrences among 60 patients with invasive breast cancer and Ki67 ≤13.25%. CONCLUSIONS: Deintensified 3-day PBI provided favorable disease control, tolerability, and cosmetic outcomes, meeting the prespecified criteria for acceptability. This approach is an attractive option for patients with small node-negative ER+ breast cancer and DCIS.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Mutter RW, Golafshar MA, Buras MR, et al. Dose Deintensified 3-Day Photon, Proton, or Brachytherapy: A Nonrandomized Controlled Partial Breast Irradiation Trial. Int J Radiat Oncol Biol Phys. 2024. PMID: 39299551. doi:10.1016/j.ijrobp.2024.09.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。